Portopulmonary hypertension epidemiology and demographics

Revision as of 18:25, 18 July 2016 by Irfan Dotani (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Portopulmonary hypertension Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Portopulmonary hypertension from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Portopulmonary hypertension epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Portopulmonary hypertension epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Portopulmonary hypertension epidemiology and demographics

CDC on Portopulmonary hypertension epidemiology and demographics

Portopulmonary hypertension epidemiology and demographics in the news

Blogs on Portopulmonary hypertension epidemiology and demographics

Directions to Hospitals Treating Portopulmonary hypertension

Risk calculators and risk factors for Portopulmonary hypertension epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Epidemiology and Demographics

PPH presents roughly equally in male and female cirrhotics; 71% female in an American series and 57% male in a larger French series.[1][2] Typically, patients present in their fifth decade, aged 49 +/- 11 years on average.[1][3]

References

  1. 1.0 1.1 Le Pavec et al. Portopulmonary Hypertension: Survival and Prognostic Factors. Am J Respir Crit Care Med Vol 178. pp 637–643, 2008
  2. Kawut SM et al. Clinical Risk Factors for Portopulmonary Hypertension. Hepatology 2008;48
  3. Bejaminov et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52:1355-1362

Template:WS Template:WH